Smoking Treatment of Prisoners (STOP)
This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: May 11, 2005
Last updated: September 29, 2008
Last verified: September 2008
The purpose of this study is to determine the efficacy of a 10-week smoking cessation therapy combined with NicoDerm CQ for smoking cessation among female prisoners.
Tobacco Use Cessation
Tobacco Use Disorder
Behavioral: 10-week smoking cessation group therapy combined with NicoDerm CQ
Endpoint Classification: Efficacy Study
Masking: Open Label
Primary Purpose: Treatment
||Smoking Treatment of Prisoners: Project "STOP"
Primary Outcome Measures:
- smoking cessation [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2007 (Final data collection date for primary outcome measure)
This is a randomized controlled trial utilizing a wait-list control group to examine 10-week group therapy and nicotine replacement compared to wait-list for smoking cessation among female prisoners.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- 1) current smoker and (2) seeking group treatment to quit smoking.
- (1) non-english speaking, (2) housed in segregation, (3) presence of active, severe mental illness as defined by active psychosis, manic episode, or imminently suicidal/homicidal, (4) mental retardation such that they cannot provide informed consent, and (5) due to be released or transferred to another facility within the next year.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110630
|Virginia Commonwealth University
|Richmond, Virginia, United States, 23298 |
||Karen Cropsey, Ph.D.
||Virginia Commonwealth University
No publications provided
||Karen Cropsey, Univeristy of Alabama at Birmingham
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 11, 2005
||September 29, 2008
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 23, 2014
Tobacco Use Disorder
Peripheral Nervous System Agents
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Central Nervous System Agents